- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07325617
Tracking AI/LLM-geletterdheid en -kennis bij urologie-patiënten (TALK-U) (TALK-U)
De TALK-U Studie: Het Volgen van AI/LLM Kennis en Gebruik in Urologische Poliklinieken en de Associatie met Angst, Tevredenheid en Gezondheidsbewustzijn - Een Cross-Sectionele Studie
This study is a one-time, questionnaire-based survey of adults attending a urology outpatient clinic. The investigators will examine whether patients who use AI chat tools based on large language models (LLMs), such as ChatGPT, before seeking care differ from non-users in (1) anxiety, (2) satisfaction with the clinic visit, and (3) awareness/understanding of their health condition.
Participants who provide written informed consent will complete a brief survey during their clinic visit (about 5-7 minutes). The survey includes a standardized anxiety scale (GAD-7), visual analog scales (0-10) for anxiety before and after the visit, satisfaction, and disease awareness, as well as questions about AI/LLM knowledge and use. Treating clinicians will not have access to participants' survey responses, and participation will not affect clinical care.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
The TALK-U study is a cross-sectional, observational survey conducted in the urology outpatient clinic of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital. The primary exposure is self-reported AI/LLM knowledge and use for health information (e.g., whether participants have used ChatGPT or similar tools, frequency, awareness of AI, and purpose of use). The primary outcome is anxiety measured by GAD-7 at the time of the clinic encounter. Secondary outcomes include (i) anxiety assessed on a 0-10 visual analog scale before and after the visit, (ii) outpatient visit satisfaction (0-10 VAS), and (iii) perceived disease awareness/understanding (0-10 VAS).
Eligible adult first-time urology outpatients who can complete the survey independently and provide informed consent will be invited during a 2-month recruitment period. Analyses will compare outcomes between AI/LLM users and non-users and explore associations with age group (<40, 40-60, >60), education level, and urology subspecialty category. Data will be analyzed using appropriate parametric/nonparametric tests depending on distribution, with p < 0.05 considered statistically significant.
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
Yenimahalle/Ankara
-
Ankara, Yenimahalle/Ankara, Turkije (Türkiye), 06200
- Dr.Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Adult patients (≥18 years) presenting for a first-time visit to the Urology Outpatient Clinic at Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital will be invited to participate during a 2-month recruitment period. Participants who provide written informed consent and can complete a brief questionnaire independently will be enrolled. The study will include both sexes and a broad range of urologic presenting complaints.
Beschrijving
Inclusion Criteria:
- Age 18 years or older
- First-time visit to the Urology Outpatient Clinic
- Able to read and write and complete the questionnaire independently
- Able to provide written informed consent
Exclusion Criteria:
- Age under 18 years
- Insufficient literacy to understand and complete the questionnaire
- Severe hearing or visual impairment, or a neurological/psychiatric condition that prevents understanding and completing the survey
- Refusal or inability to provide informed consent
- Currently under follow-up for a known urologic condition (i.e., not a first-time urology outpatient visit)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: CASE_CONTROL
- Tijdsperspectieven: CROSS_SECTIONAL
Cohorten en interventies
Groep / Cohort |
|---|
|
AI/LLM users
Participants who report prior use of AI chat tools based on large language models (e.g., ChatGPT or similar) for health information before the outpatient urology visit, as assessed by the study questionnaire. |
|
non AI/LLM users
Participants who report no prior use of AI/LLM chat tools (e.g., ChatGPT or similar) for health information before the outpatient urology visit, as assessed by the study questionnaire. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Pre-visit Anxiety (VAS 0-10)
Tijdsspanne: Day 0 (immediately before the outpatient visit)
|
Self-rated anxiety on a 0-10 visual analog scale (VAS), where 0 indicates no anxiety and 10 indicates the highest possible anxiety. This measure reflects visit-related state anxiety prior to clinician encounter. |
Day 0 (immediately before the outpatient visit)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Post-visit Anxiety (VAS 0-10)
Tijdsspanne: Day 0 (immediately after the outpatient visit)
|
Self-rated anxiety on a 0-10 VAS (0 = none, 10 = highest). |
Day 0 (immediately after the outpatient visit)
|
|
Visit Satisfaction (VAS 0-10)
Tijdsspanne: Day 0 (immediately after the outpatient visit)
|
Self-rated satisfaction with the outpatient visit on a 0-10 VAS (0 = not satisfied at all, 10 = maximum satisfaction). |
Day 0 (immediately after the outpatient visit)
|
|
Disease Awareness/Understanding (VAS 0-10)
Tijdsspanne: Day 0 (during the outpatient clinic visit)
|
Self-rated awareness/understanding of one's condition on a 0-10 VAS (0 = none, 10 = complete). |
Day 0 (during the outpatient clinic visit)
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Baseline General Anxiety Symptoms (GAD-7 Total Score)
Tijdsspanne: Day 0 (at enrollment; prior to or during the clinic visit)
|
Total score on the 7-item GAD-7 questionnaire (range 0-21; higher scores indicate greater generalized anxiety symptoms). This measure will be used to account for baseline anxiety (trait-like symptoms) and to adjust analyses of VAS-based state anxiety out |
Day 0 (at enrollment; prior to or during the clinic visit)
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2025-06/98
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .